NeoGenomics Expands Precision Oncology Portfolio with Eight ASCO 2026 Abstracts
Event summary
- NeoGenomics will present eight scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, in Chicago.
- Research spans hematologic malignancies, solid-tumor genomic profiling, and real-world impact of insurance coverage gaps on NGS testing.
- New biomarkers highlighted include B7-H3, CD137, EZH2, and PRMT5 to support biopharma partners.
- Company debuts updated mission and vision focused on personalized cancer treatment decisions.
- Introduces a low-sample-input AML MRD flow assay for higher sensitivity and faster turnaround times.
The big picture
NeoGenomics' ASCO 2026 presentations underscore its strategic pivot toward deeper integration of precision oncology solutions across the cancer continuum. The focus on real-world evidence and novel biomarkers aligns with broader industry trends toward personalized medicine and value-based healthcare. The company's expanded capabilities in genomic profiling and MRD detection position it to capture a larger share of the growing oncology diagnostics market, particularly as biopharma partners seek more sophisticated tools for drug development and clinical trials.
What we're watching
- Clinical Adoption
- How the expanded capabilities in hematologic malignancies and solid-tumor profiling will affect NeoGenomics' market share.
- Regulatory Impact
- Whether the real-world evidence on insurance coverage gaps will influence policy changes in NGS testing reimbursement.
- Biopharma Collaboration
- The pace at which NeoGenomics can integrate new biomarkers into its offerings to support biopharma partners.
Related topics